Novabio Therapeutics

Shanghai Saierxin Biomedical Technology Co., Ltd. was founded in 2022, focusing on the development of multimodal Treg cell therapies for treating neurodegenerative diseases, autoimmune diseases, and metabolic disorders. In these disease areas, many indications remain untreatable or lack effective therapeutic options in clinical practice. After years of research, we have discovered that Treg can effectively suppress the proliferation and function of pro-inflammatory cells in autoimmune diseases from multiple aspects, thereby achieving therapeutic effects.